{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T13:47:21Z","timestamp":1776692841765,"version":"3.51.2"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,6]]},"abstract":"<jats:sec><jats:title>Background.<\/jats:title><jats:p>Hepatitis C virus-positive (HCV+) kidney transplant (KT) recipients are at increased risks of rejection and graft failure. The optimal induction agent for this population remains controversial, particularly regarding concerns that antithymocyte globulin (ATG) might increase HCV-related complications.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>Using Scientific Registry of Transplant Recipients and Medicare claims data, we studied 6780 HCV+ and 139 681 HCV\u2212 KT recipients in 1999\u20132016 who received ATG or interleukin-2 receptor antagonist (IL2RA) for induction. We first examined the association of recipient HCV status with receiving ATG (versus IL2RA) using multilevel logistic regression. Then, we studied the association of ATG (versus IL2RA) with KT outcomes (rejection, graft failure, and death) and hepatic complications (liver transplant registration and cirrhosis) among HCV+ recipients using logistic and Cox regression.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>HCV+ recipients were less likely to receive ATG than HCV\u2212 recipients (living donor, adjusted odds ratio [aOR] =<jats:sub>0.64<\/jats:sub>0.77<jats:sub>0.91<\/jats:sub>; deceased donor, aOR =<jats:sub>0.71<\/jats:sub>0.81<jats:sub>0.92<\/jats:sub>). In contrast, HCV+ recipients who received ATG were at lower risk of acute rejection compared to those who received IL2RA (1-y crude incidence = 11.6% versus 12.6%; aOR =<jats:sub>0.68<\/jats:sub>0.82<jats:sub>0.99<\/jats:sub>). There was no significant difference in the risks of graft failure (adjusted hazard ratio [aHR] =<jats:sub>0.86<\/jats:sub>1.00<jats:sub>1.17<\/jats:sub>), death (aHR =<jats:sub>0.85<\/jats:sub>0.95<jats:sub>1.07<\/jats:sub>), liver transplant registration (aHR =<jats:sub>0.58<\/jats:sub>0.97<jats:sub>1.61<\/jats:sub>), and cirrhosis (aHR =<jats:sub>0.73<\/jats:sub>0.92<jats:sub>1.16<\/jats:sub>).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions.<\/jats:title><jats:p>Our findings suggest that ATG, as compared to IL2RA, may lower the risk of acute rejection without increasing hepatic complications in HCV+ KT recipients. Given the higher rates of acute rejection in this population, ATG appears to be safe and reasonable for HCV+ recipients.<\/jats:p><\/jats:sec>","DOI":"10.1097\/tp.0000000000002959","type":"journal-article","created":{"date-parts":[[2019,9,19]],"date-time":"2019-09-19T16:11:51Z","timestamp":1568909511000},"page":"1294-1303","source":"Crossref","is-referenced-by-count":6,"title":["Antithymocyte Globulin Versus Interleukin-2 Receptor Antagonist in Kidney Transplant Recipients With Hepatitis C Virus"],"prefix":"10.1097","volume":"104","author":[{"given":"Sunjae","family":"Bae","sequence":"first","affiliation":[{"name":"Department of Epidemiology, Johns Hopkins School of Public Health, Baltimore, MD."},{"name":"Department of Biostatistics, Johns Hopkins School of Public Health, Baltimore, MD."},{"name":"Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine M.","family":"Durand","sequence":"additional","affiliation":[{"name":"Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacqueline M.","family":"Garonzik-Wang","sequence":"additional","affiliation":[{"name":"Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric K.H.","family":"Chow","sequence":"additional","affiliation":[{"name":"Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren M.","family":"Kucirka","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Johns Hopkins School of Public Health, Baltimore, MD."},{"name":"Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mara A.","family":"McAdams-DeMarco","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Johns Hopkins School of Public Health, Baltimore, MD."},{"name":"Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allan B.","family":"Massie","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Johns Hopkins School of Public Health, Baltimore, MD."},{"name":"Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fawaz","family":"Al Ammary","sequence":"additional","affiliation":[{"name":"Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josef","family":"Coresh","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Johns Hopkins School of Public Health, Baltimore, MD."},{"name":"Department of Biostatistics, Johns Hopkins School of Public Health, Baltimore, MD."},{"name":"Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorry L.","family":"Segev","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Johns Hopkins School of Public Health, Baltimore, MD."},{"name":"Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"issue":"Suppl 2)","key":"R1-20231002","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/ajt.13666","article-title":"Kidney.","volume":"16","author":"Hart","year":"2016","journal-title":"Am J Transplant"},{"issue":"11","key":"R2-20231002","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1097\/TP.0b013e3181f92548","article-title":"Adverse impact of hepatitis C virus infection on renal replacement therapy and renal transplant patients in Australia and New Zealand.","volume":"90","author":"Scott","year":"2010","journal-title":"Transplantation"},{"issue":"5","key":"R3-20231002","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1097\/01.TP.0000131948.29742.24","article-title":"Hepatitis C infection, time in renal-replacement therapy, and outcome after kidney transplantation.","volume":"78","author":"Bruchfeld","year":"2004","journal-title":"Transplantation"},{"issue":"5","key":"R4-20231002","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1097\/00007890-199803150-00011","article-title":"Harmful long-term impact of hepatitis C virus infection in kidney transplant recipients.","volume":"65","author":"Legendre","year":"1998","journal-title":"Transplantation"},{"issue":"4","key":"R5-20231002","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/00007890-199808270-00010","article-title":"Retrospective study on the impact of hepatitis C virus infection on kidney transplant patients over 20 years.","volume":"66","author":"Hanafusa","year":"1998","journal-title":"Transplantation"},{"issue":"5","key":"R6-20231002","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/j.1399-0012.2011.01583.x","article-title":"The impact of hepatitis C virus donor and recipient status on long-term kidney transplant outcomes: University Of Wisconsin Experience.","volume":"26","author":"Singh","year":"2012","journal-title":"Clin Transplant"},{"issue":"19","key":"R7-20231002","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1056\/NEJMoa060068","article-title":"Rabbit antithymocyte globulin versus basiliximab in renal transplantation.","volume":"355","author":"Brennan","year":"2006","journal-title":"N Engl J Med"},{"issue":"6","key":"R8-20231002","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1681\/ASN.2008101037","article-title":"Daclizumab versus antithymocyte globulin in high-immunological-risk renal transplant recipients.","volume":"20","author":"No\u00ebl","year":"2009","journal-title":"J Am Soc Nephrol"},{"issue":"7","key":"R9-20231002","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1111\/ajt.13191","article-title":"Daclizumab versus rabbit antithymocyte globulin in high-risk renal transplants: five-year follow-up of a randomized study.","volume":"15","author":"Hellemans","year":"2015","journal-title":"Am J Transplant"},{"issue":"Suppl 3)","key":"R10-20231002","first-page":"S1","article-title":"KDIGO clinical practice guideline for the care of kidney transplant recipients.","volume":"9","year":"2009","journal-title":"Am J Transplant"},{"issue":"7","key":"R11-20231002","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1111\/j.1600-6143.2005.00918.x","article-title":"Natural history of hepatitis C virus-related liver fibrosis after renal transplantation.","volume":"5","author":"Kamar","year":"2005","journal-title":"Am J Transplant"},{"issue":"3","key":"R12-20231002","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1086\/315355","article-title":"Longitudinal analysis of hepatitis C virus replication and liver fibrosis progression in renal transplant recipients.","volume":"181","author":"Izopet","year":"2000","journal-title":"J Infect Dis"},{"issue":"9","key":"R13-20231002","first-page":"1453","article-title":"Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation.","volume":"92","author":"Rosen","year":"1997","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"R14-20231002","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/ndt\/17.1.129","article-title":"Severe evolution of chronic hepatitis C in renal transplantation: a case control study.","volume":"17","author":"Zylberberg","year":"2002","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"R15-20231002","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1681\/ASN.2010060668","article-title":"Effect of kidney transplantation on outcomes among patients with hepatitis C.","volume":"22","author":"Roth","year":"2011","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"R16-20231002","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1097\/TP.0b013e3181722f3a","article-title":"Impact of immunosuppressive regimen on survival of kidney transplant recipients with hepatitis C.","volume":"85","author":"Luan","year":"2008","journal-title":"Transplantation"},{"issue":"1","key":"R17-20231002","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.2517-6161.1993.tb01468.x","article-title":"Modelling complexity: applications of Gibbs sampling in medicine.","volume":"55","author":"Gilks","year":"1993","journal-title":"J R Stat Soc Ser B Methodol"},{"issue":"4","key":"R18-20231002","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.2307\/2533673","article-title":"A general framework for random effects survival analysis in the Cox proportional hazards setting.","volume":"54","author":"Sargent","year":"1998","journal-title":"Biometrics"},{"issue":"3","key":"R19-20231002","first-page":"671","article-title":"A class of multivanate failure time distributions.","volume":"73","author":"Hougaard","year":"1986","journal-title":"Biometrika"},{"issue":"7","key":"R20-20231002","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/pds.3290","article-title":"Validation of three coding algorithms to identify patients with end-stage liver disease in an administrative database.","volume":"21","author":"Goldberg","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"3","key":"R21-20231002","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1365-2036.2007.03572.x","article-title":"The validity of viral hepatitis and chronic liver disease diagnoses in Veterans Affairs administrative databases.","volume":"27","author":"Kramer","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"issue":"446","key":"R22-20231002","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk.","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"issue":"2","key":"R23-20231002","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/aje\/kwp107","article-title":"Competing risk regression models for epidemiologic data.","volume":"170","author":"Lau","year":"2009","journal-title":"Am J Epidemiol"},{"issue":"9","key":"R24-20231002","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1097\/01.tp.0000179639.98338.39","article-title":"Posttransplant lymphoproliferative disorders after renal transplantation in the united states in era of modern immunosuppression.","volume":"80","author":"Caillard","year":"2005","journal-title":"Transplantation"},{"issue":"1","key":"R26-20231002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/biostatistics\/kxn014","article-title":"Effective communication of standard errors and confidence intervals.","volume":"10","author":"Louis","year":"2009","journal-title":"Biostatistics"},{"issue":"10","key":"R27-20231002","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1111\/tri.12167","article-title":"Campath induction in HCV and HCV\/HIV-seropositive kidney transplant recipients.","volume":"26","author":"Vivanco","year":"2013","journal-title":"Transpl Int"},{"issue":"5","key":"R28-20231002","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.transproceed.2011.12.076","article-title":"Kidney transplantation in hepatitis C-positive recipients: does type of induction influence outcomes?","volume":"44","author":"Sureshkumar","year":"2012","journal-title":"Transplant Proc"},{"issue":"8","key":"R29-20231002","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nri.2016.69","article-title":"Immune responses and immunopathology in acute and chronic viral hepatitis.","volume":"16","author":"Shin","year":"2016","journal-title":"Nat Rev Immunol"},{"issue":"12","key":"R30-20231002","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1053\/jlts.2001.29414","article-title":"Anti-interleukin-2 receptor therapy in combination with mycophenolate mofetil is associated with more severe hepatitis C recurrence after liver transplantation.","volume":"7","author":"Nelson","year":"2001","journal-title":"Liver Transpl"},{"key":"R31-20231002","doi-asserted-by":"crossref","first-page":"S115","DOI":"10.1007\/s001470050441","article-title":"Hepatitis C virus genotypes and the influence of the induction of immunosuppression with anti-thymocyte globulin (ATG) on chronic hepatitis in renal graft recipients.","volume":"11 Suppl 1","author":"Rodrigues","year":"1998","journal-title":"Transpl Int"},{"issue":"2","key":"R32-20231002","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/tri.13079","article-title":"Center practice drives variation in choice of US kidney transplant induction therapy: a retrospective analysis of contemporary practice.","volume":"31","author":"Dharnidharka","year":"2018","journal-title":"Transpl Int"},{"issue":"4","key":"R33-20231002","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.kint.2018.06.011","article-title":"Executive summary of the 2018 KDIGO hepatitis C in CKD guideline: welcoming advances in evaluation and management.","volume":"94","author":"Jadoul","year":"2018","journal-title":"Kidney Int"},{"issue":"5","key":"R34-20231002","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1111\/ajt.13620","article-title":"Successful treatment of hepatitis C in renal transplant recipients with direct-acting antiviral agents.","volume":"16","author":"Sawinski","year":"2016","journal-title":"Am J Transplant"},{"issue":"8","key":"R35-20231002","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1111\/ajt.13758","article-title":"National variation in use of immunosuppression for kidney transplantation: A call for evidence-based regimen selection.","volume":"16","author":"Axelrod","year":"2016","journal-title":"Am J Transplant"},{"issue":"5","key":"R36-20231002","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/S1473-3099(12)70010-5","article-title":"Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine.","volume":"12","author":"Grebely","year":"2012","journal-title":"Lancet Infect Dis"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000002959","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T19:39:45Z","timestamp":1721763585000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000002959"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000002959","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]}}}